Markets & Investing
Huxley Health finalizes Sintalica deal, names Bruce Linton as new Chairman
Privately-owned psychedelics company Huxley Health Inc. has completed its acquisition of Canadian drug discovery company Sintalica and named Bruce Linton…
Privately-owned psychedelics company Huxley Health Inc. has completed its acquisition of Canadian drug discovery company Sintalica and named Bruce Linton as its new Chairman.
Sintalica operates through its Italian subsidiary focused on using psychedelics to create treatments for neuroinflammatory disorders. Sintalica has filed four provisional patents for proprietary psychedelic molecules with unique properties, improved stability and safety profiles, and enhanced bioavailability. The deal was an all-stock transaction valued at $7.2 million.
Former Canopy Growth founder and CEO Bruce Linton was named as the company’s new Chairman replacing Michael Marchese, who previously served as the company’s only director. Linton is also chair of the advisory board of Red Light Holland Corp. (CSE:TRIP).
Linton said, “As a Co-Founder and Chairman of Huxley, I’m excited to help steward this innovative company and make a profound impact on healthcare discoveries.”
New team
The company continued to beef up its board and C-suite with an all-male team featuring new board members Fabian Monaco who was also the co-founder and former CEO of Gage Growth Corp., which was acquired by TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) and investor John Di Girolamo.
Huxley named Jared Rhines as its new Chief Executive Officer. Rhines’ experience spans clinical research, regulatory affairs, sales, marketing, and market access in multiple therapeutic areas, including rare diseases, neurology, cardiology, and critical care. He along with 5 colleagues, founded INO Therapeutics, a company that was eventually acquired for $2.3 billion.
The new Chief Science Officer is George Jackowski, PhD who has experience clearing 25 products through the FDA, commercializing them globally, with revenues exceeding $10 billion, he holds over 200+ issued patents. Peter Kampian was named the Chief Financial Officer.
Together Huxley and Sintalica have raised $6 million. The company has also successfully filed over 10 U.S. Patents protecting its intellectual property portfolio, including candidates undergoing pre-clinical testing.
The post Huxley Health finalizes Sintalica deal, names Bruce Linton as new Chairman appeared first on Green Market Report.
psychedelics psychedelic tsx cse deal fda research
-
Law & Regulation1 week agoClearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psychedelics1 week agoCybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
-
Psilocybin1 week agoCalifornia advances bill for psychedelics centers
-
Psilocybin4 days agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week agoPsychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics1 week agoRevive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
-
Psychedelics4 days agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics4 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID